Literature DB >> 21505234

Cocrystallization studies of full-length recombinant butyrylcholinesterase (BChE) with cocaine.

Oluwatoyin Ajibola Asojo1, Oluyomi Adebola Asojo, Michelle N Ngamelue, Kohei Homma, Oksana Lockridge.   

Abstract

Human butyrylcholinesterase (BChE; EC 3.1.1.8) is a 340 kDa tetrameric glycoprotein that is present in human serum at about 5 mg l(-1) and has well documented therapeutic effects on cocaine toxicity. BChE holds promise as a therapeutic that reduces and finally eliminates the rewarding effects of cocaine, thus weaning an addict from the drug. There have been extensive computational studies of cocaine hydrolysis by BChE. Since there are no reported structures of BChE with cocaine or any of the hydrolysis products, full-length monomeric recombinant wild-type BChE was cocrystallized with cocaine. The refined 3 Å resolution structure appears to retain the hydrolysis product benzoic acid in sufficient proximity to form a hydrogen bond to the active-site Ser198.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21505234      PMCID: PMC3080143          DOI: 10.1107/S1744309111004805

Source DB:  PubMed          Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun        ISSN: 1744-3091


  41 in total

1.  Characterization of butyrylcholinesterase antagonism of cocaine-induced hyperactivity.

Authors:  Lee Koetzner; James H Woods
Journal:  Drug Metab Dispos       Date:  2002-06       Impact factor: 3.922

2.  Half-life of plasma cholinesterase.

Authors:  D Ostergaard; J Viby-Mogensen; H K Hanel; L T Skovgaard
Journal:  Acta Anaesthesiol Scand       Date:  1988-04       Impact factor: 2.105

3.  Solvent content of protein crystals.

Authors:  B W Matthews
Journal:  J Mol Biol       Date:  1968-04-28       Impact factor: 5.469

Review 4.  Enhancing cocaine metabolism with butyrylcholinesterase as a treatment strategy.

Authors:  D A Gorelick
Journal:  Drug Alcohol Depend       Date:  1997-12-15       Impact factor: 4.492

5.  Crystallization and X-ray structure of full-length recombinant human butyrylcholinesterase.

Authors:  Michelle N Ngamelue; Kohei Homma; Oksana Lockridge; Oluwatoyin A Asojo
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2007-08-10

6.  Attenuation of cocaine-induced locomotor activity by butyrylcholinesterase.

Authors:  G N Carmona; C W Schindler; M Shoaib; R Jufer; E J Cone; S R Goldberg; N H Greig; Q S Yu; D A Gorelick
Journal:  Exp Clin Psychopharmacol       Date:  1998-08       Impact factor: 3.157

7.  Wild-type and A328W mutant human butyrylcholinesterase tetramers expressed in Chinese hamster ovary cells have a 16-hour half-life in the circulation and protect mice from cocaine toxicity.

Authors:  Ellen G Duysen; Cynthia F Bartels; Oksana Lockridge
Journal:  J Pharmacol Exp Ther       Date:  2002-08       Impact factor: 4.030

8.  Use of cholinesterases as pretreatment drugs for the protection of rhesus monkeys against soman toxicity.

Authors:  A D Wolfe; D W Blick; M R Murphy; S A Miller; M K Gentry; S L Hartgraves; B P Doctor
Journal:  Toxicol Appl Pharmacol       Date:  1992-12       Impact factor: 4.219

9.  Tissue distribution of human acetylcholinesterase and butyrylcholinesterase messenger RNA.

Authors:  O Jbilo; C F Bartels; A Chatonnet; J P Toutant; O Lockridge
Journal:  Toxicon       Date:  1994-11       Impact factor: 3.033

Review 10.  The integration of macromolecular diffraction data.

Authors:  Andrew G W Leslie
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2005-12-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.